On May 23, 2018, Health Canada published Overview of the Reporting Adverse Reactions to Marketed Health Products - Guidance Document for Industry. “This guidance document provides market authorization holders (MAHs) with assistance on how to comply with the Food and Drugs Act, the Food and Drug Regulations and the Natural Health Products Regulations with respect to reporting adverse reactions (ARs) to marketed health products”, including: pharmaceutical drugs, biologics, radiopharmaceutical drugs and natural health products. These ARs are to be reported to the Canada Vigilance Program of the Marketed Health Products Directorate (MHPD) of Health Canada.
Related Publications & Articles
-
Health Canada releases notice on aligned reviews between Health Canada and health technology assessment organizations
On November 5, 2024, Health Canada released the Notice to industry: Aligned reviews between Health Canada and health technology assessment organizations.Read More -
Health Canada posts 2023 to 2024 review on drug shortages
On November 20, 2024, Health Canada posted Drug shortages in Canada: Fiscal year 2023 to 2024 in review.Read More -
Agile licensing amendments registered
Following consultation starting in 2022, on November 29, 2024, Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) were registered.Read More